nct_id,DRUGNAME,DRUGTYPE,DISEASES,DRUGSTAT,TARGNAME
NCT04730323,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04583592,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04583592,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04583592,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04345601,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04715763,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04681430,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04681430,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04681430,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04623021,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04623021,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04623021,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04604704,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04474457,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04469114,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04452097,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04411433,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04411433,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04411433,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04411433,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04363827,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04362813,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04357808,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04336332,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04331600,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04331600,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04331600,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04649021,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04640168,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04640168,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04640168,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04640168,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04593940,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04593940,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04593940,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04591210,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04591210,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04546581,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04546581,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04546581,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04530617,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04530617,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04530617,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04501978,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04501978,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04501978,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04357366,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04322396,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04322396,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04312009,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04311177,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04655586,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04649151,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04529525,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04470427,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04419025,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04373733,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04363502,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04338828,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04335201,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04331834,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328012,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04283461,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04472585,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04472585,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04681053,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04678830,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5)   CCR5_HUMAN
NCT04678739,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04678739,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04678739,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04678739,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04673162,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04673149,gls-5300,Vaccine,Middle East Respiratory Syndrome (MERS),Drug in Phase 1/2 Clinical Trial,
NCT04672564,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04669990,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04669990,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04669990,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04668469,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04668469,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04668209,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2)   CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN
NCT04667780,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04664010,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04664010,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04664010,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04661540,cm4620,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04661527,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04530604,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04530578,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04528927,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04528888,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04528888,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04527562,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04527211,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04524663,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04524663,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04524663,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04523571,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04523090,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04522986,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04273581,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04522466,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04521400,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04521400,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04521400,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04411433,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04388826,veru-111,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04388683,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04372589,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04367883,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04363346,ft516,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04351724,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351724,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04351724,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04351724,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04351724,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04346199,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN
NCT04341584,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04537949,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04476706,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04445272,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04380701,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04380701,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04380701,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04380701,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04369469,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04353180,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04353180,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04353180,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04315948,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04315948,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04315948,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04315948,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04315948,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04315948,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04466241,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04466241,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04409262,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04409262,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04409262,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04409262,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04663737,silmitasertib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN casein kinase II (CSK2)   CSK21_HUMAN; CSK22_HUMAN; CSK23_HUMAN; CSK2B_HUMAN
NCT04402970,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04382625,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04358549,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04330586,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04662086,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04662086,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04662086,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04662073,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04662073,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04662073,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04615429,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04492475,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04492475,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04492475,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04492475,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04486508,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04486508,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04486313,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04482712,rapamycin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN
NCT04482712,rapamycin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN
NCT04359680,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04359095,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348383,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348071,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04659772,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04657458,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04652648,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04652115,defibrotide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04647695,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04647695,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04647695,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04647695,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04647669,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04647669,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04647669,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04647669,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN
NCT04647669,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04646109,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04636671,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04635943,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04635241,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04634370,natural killer cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04633772,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04632706,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04519385,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04516941,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04516915,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN
NCT04516915,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04516811,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04510662,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04510493,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04505774,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04505774,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04501783,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04499677,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04499677,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04499313,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04498936,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04497948,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN
NCT04497519,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04494724,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04494399,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04494399,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04494399,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04494399,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04493359,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04492358,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04380961,sirukumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04703608,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04428268,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04428268,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04428268,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04421027,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04412291,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04412291,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04716569,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04642638,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04600141,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04600141,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04600141,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04583969,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN
NCT04583969,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04583969,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04583969,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04583956,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04583956,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04583956,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04539262,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04539262,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04539262,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04510194,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN
NCT04510038,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04464408,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04405739,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04405570,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04360096,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04334148,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04727424,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04727424,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN
NCT04727775,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04727775,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04727775,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04727775,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04724629,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04723563,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04720612,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04718480,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04718285,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04714515,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04714515,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04712279,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04711863,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04492501,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04492501,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04492501,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04492501,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04492501,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04490239,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04489446,sildenafil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN phosphodiesterase type 5 (PDE5)   PDE5A_HUMAN
NCT04488081,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04488081,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04488081,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04487990,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04487886,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG) PK3CG_HUMAN
NCT04485429,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04485429,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04485130,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO)        R1AB_CVHSA (PL-PRO)
NCT04485130,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO)        R1AB_CVEMC (PL-PRO)
NCT04485130,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04483960,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04483960,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04483960,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04482686,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04479358,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04479358,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04477993,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04477083,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04476992,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04476992,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04476979,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04473053,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04473053,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04473053,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04470544,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04470544,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04470544,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04469491,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04467931,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04467931,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04467931,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04467047,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04466670,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04466670,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04466540,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04466280,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04466098,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04465695,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04463264,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04462757,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04461353,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04461340,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN
NCT04460547,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04460547,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04460547,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04460547,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04460183,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04459702,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04459702,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04459702,lopinavir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV 3C-like protease (3CLpro)      R1AB_CVHSA (3CLpro)
NCT04459702,lopinavir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV 3C-like proteinase (3CLpro)    R1AB_CVEMC (3CLpro)
NCT04459676,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04458948,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04458948,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04457609,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04457609,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04457609,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04456361,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04455958,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04455815,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04455815,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04455815,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04455243,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04629105,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04628143,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04628143,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04628143,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04627467,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04627467,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04627467,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04626089,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN
NCT04625985,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN
NCT04625738,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04625114,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04625114,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04625114,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04625114,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04625114,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04625114,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04622891,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04619680,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04613271,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04613271,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04610541,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04610541,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04610541,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04608266,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04608266,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04608266,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04608214,alisporivir,Protein/peptide drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN cyclophilin A (CYPA)      PPIA_HUMAN
NCT04608214,alisporivir,Protein/peptide drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN cyclophilin A (CYPA)      PPIA_HUMAN
NCT04606563,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04605887,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04605588,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04605588,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04605588,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04605588,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04605588,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04604678,metformin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN mannose receptor (MRC1)   MRC1_HUMAN
NCT04604678,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04604327,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04603742,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04603729,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04603690,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04602507,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04601077,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04600999,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04600895,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04597775,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04596839,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04596839,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04596839,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04594343,disulfiram,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV papain-like proteinase (PL-PRO)        R1AB_CVHSA (PL-PRO)
NCT04594343,disulfiram,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV papain-like proteinase (PL-PRO)        R1AB_CVEMC (PL-PRO)
NCT04594343,disulfiram,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04590274,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04590274,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04588480,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04586153,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04584580,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04582266,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04582266,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04582266,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04581954,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04577534,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04577378,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04577378,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04575064,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04575064,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04575064,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04575558,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04570501,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04570449,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04570397,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04570254,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04569383,mva-sars-2,Vaccine,Middle East Respiratory Syndrome (MERS),Discontinue Drug in Phase 1 Clinical Trial,
NCT04566276,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04565665,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04343248,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04340232,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04335084,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04668950,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04643678,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04511923,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04409483,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04381936,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04381936,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04381936,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04381936,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04381936,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04381936,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04381936,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04372602,duvelisib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN PI3-kinase gamma (PIK3CG) PK3CG_HUMAN
NCT04368728,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04368728,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04349371,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04349371,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04349371,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04337918,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04337918,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04730206,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04730206,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04730206,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04713553,bnt162b2,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04680949,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04652765,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04652765,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04652765,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04431453,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04431453,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04431453,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04405076,mrna-1273,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04391309,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04391309,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04391309,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04376814,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04376814,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04376814,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04376684,otilimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN
NCT04366050,ramipril,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme (ACE)       ACE_HUMAN
NCT04375202,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04374942,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04374552,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04374461,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04374149,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04374071,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04374032,metenkefalin + tridecactide,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04374019,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04374019,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04374019,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04374019,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04373824,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04373044,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04373044,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04372628,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04372082,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04372082,diltiazem + niclosamide,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04372017,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04371978,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN
NCT04371926,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04371822,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04371822,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04371822,snpp protoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04371822,sulfonatoporphyrin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04371640,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN
NCT04371601,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04371523,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04371406,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04371367,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR)       C5AR1_HUMAN
NCT04371107,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04370834,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04370782,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04370782,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04370288,"mcn (methylene blue, vitamin c, n-acetyl cysteine)",Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04370262,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04370015,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04369742,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04364022,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04369365,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04366323,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04368351,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04368351,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04367831,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04367831,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04367168,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04366739,chlorpromazine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04366739,chlorpromazine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04366739,chlorpromazine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04366271,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04366232,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04366115,avm0703,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04366089,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04366089,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04365985,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04365985,ketamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04365725,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04365725,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04365725,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04365582,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04365582,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04365582,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04365517,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN
NCT04365231,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04365127,progesterone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04365101,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04364984,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04364815,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04364009,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04363866,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04363853,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04363736,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04363450,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04363437,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04363203,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04363203,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04362332,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04362332,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04362332,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04362332,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04362189,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04362137,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04362111,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04361942,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04361552,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04361461,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04361461,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04361422,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04361214,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN
NCT04361032,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04361032,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04360980,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04360759,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04360551,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04360122,levamisole + isoprinosine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04359953,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04359953,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04359953,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04359901,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04453839,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04452474,olokizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04451291,decidual stromal cells (dsc),Protein/peptide drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,HUMAN dibasic-processing enzyme (Furin) FURIN_HUMAN
NCT04449380,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04448119,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04447833,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04447781,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04447534,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04447534,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04447534,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04447235,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04447235,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04446104,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04446104,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04445467,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04445454,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04445311,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04444986,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04444986,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04444674,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04444271,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04443881,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04443868,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04443270,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04443270,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04443270,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04441424,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04441398,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04438980,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04438850,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04438837,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04437693,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04435808,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04435717,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04435717,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04435587,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04435314,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04435015,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04435015,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04435015,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04434248,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04434144,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04431466,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04429867,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04429763,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04425707,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04425460,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04425382,darunavir + cobicistat,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04425382,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04423861,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04423042,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04421664,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04420247,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04420247,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04420247,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04420247,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04418128,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04418128,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04418128,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04416139,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04415151,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04414241,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04412772,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04412252,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04410562,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04410354,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04410354,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04410354,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04410354,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04409834,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04409834,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04408326,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04407507,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04407000,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04407000,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04406389,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04406246,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04405921,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04405921,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04403685,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04403555,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04403243,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04403243,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04403100,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04403100,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04403100,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04402203,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04401579,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04401579,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04401579,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04401579,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400838,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04400032,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04400019,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04399889,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04399798,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04399746,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04399746,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04398290,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04398004,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04397796,bm-mscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04397510,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04397328,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04395768,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04395768,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04394442,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04394416,imatinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04394416,imatinib,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl)  BCR_HUMAN-ABL1_HUMAN
NCT04394416,imatinib,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN fusion protein Bcr-Abl (Bcr-Abl)  BCR_HUMAN-ABL1_HUMAN
NCT04394377,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04394182,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04394182,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04394182,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04394182,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04394182,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04394117,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04393805,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04392713,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04392219,eidd-2801,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04392128,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04392128,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04391127,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04391127,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04390594,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04390594,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04390594,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04390464,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04390464,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04390152,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04390061,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04390061,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04390022,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04389580,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04389580,isotretinoin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 papain-like proteinase (PL-PRO)        R1AB_SARS2 (PL-PRO)
NCT04389359,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04389320,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04388709,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04387786,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04387760,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04387760,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04386876,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04386876,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04386239,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04386070,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04386070,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04385264,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT03183570,asc09 + ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT03331445,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT03852537,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT03871491,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT03891420,galidesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT03891420,galidesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT03891420,galidesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT03808922,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT03808922,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT03808922,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04708327,naltrexone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04699097,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04694612,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04694612,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04694612,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04694612,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04693026,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04693026,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04693026,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04693026,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04693026,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04690920,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04306705,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04306393,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04305106,bevacizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN vascular endothelial growth factor (VEGF) VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN
NCT04305457,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04304313,sildenafil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN phosphodiesterase type 5 (PDE5)   PDE5A_HUMAN
NCT04303507,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04302766,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04302766,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04302766,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04302519,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04299724,pathogen-specific aapc,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04298060,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04295551,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04293887,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04292899,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04292899,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04292899,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04292730,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04292730,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04292730,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04290871,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04290858,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04288713,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04287686,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04286503,carrimycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04286503,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04280705,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04280705,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04280705,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04280588,fingolimod,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04276688,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04276688,ribavirin,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04276688,ribavirin,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04276688,ribavirin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04276688,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04275414,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04275388,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04275245,merimepodib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) IMDH2_HUMAN
NCT04273763,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04273529,thalidomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04273321,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04268537,thymosin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04263402,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04263402,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04261517,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04261907,asc09 + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04261907,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04261270,asc09 + ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04261270,ritonavir + oseltamivir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04261270,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04260594,arbidol,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04257656,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04257656,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04257656,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04255017,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04255017,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04252664,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04252664,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04252664,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04252274,darunavir + cobicistat,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04251871,lopinavir + ritonavir + interferon apha + traditional chinese medicines granules,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04251871,lopinavir + ritonavir + interferon apha + traditional chinese medicines granules,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04244591,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04148430,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04561219,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04561063,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04560231,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04560231,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04560231,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04560205,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04559113,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04558463,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04558463,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04554979,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04552483,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04552379,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04552366,ad5-ncov,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04545541,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04545008,n-acetylcysteine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04542694,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04542408,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04542213,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN
NCT04541680,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04539873,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04537351,cynk-001,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04536350,aviptadil,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04536051,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04536051,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04535856,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04534725,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04534725,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04534725,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN
NCT04532931,amodiaquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,
NCT04532931,amodiaquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,
NCT04532372,leflunomide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN
NCT04384458,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04384458,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04384380,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04383717,levamisole + isoprinosine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04383717,azithromycin + hydroxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04382066,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04382053,dfv890,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04383002,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04382846,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04381364,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04382547,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04382066,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04382066,plitidepsin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04382040,artemic,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04381988,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04381962,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04381884,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04381052,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04729491,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04729491,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04380818,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04380818,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04380818,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04380818,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04380818,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04380688,acalabrutinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN bruton tyrosine kinase (BTK)      BTK_HUMAN
NCT04380519,olokizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04380402,atorvastatin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN MYD88-NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)     N.A.
NCT04380376,melphalan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04379518,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04379518,rintatolimod,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN toll-like receptor 3 (TLR3)       TLR3_HUMAN
NCT04379492,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04379479,dialyzable leukocyte cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04379310,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04379271,imu-838,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN dihydroorotate dehydrogenase (DHODH)      PYRD_HUMAN
NCT04728880,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04728880,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04728880,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04377750,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04377711,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04377659,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04377646,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04377620,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04377503,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04377503,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04377308,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04359667,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04359654,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04359615,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04359615,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04359537,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04359316,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04359316,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04359290,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04359212,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04358588,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04358068,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04358068,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04357860,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04357860,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04357535,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04356937,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04356690,etoposide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04356495,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04356495,ciclesonide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04356495,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04355936,telmisartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04355793,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04355728,mesenchymal stem cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04355676,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04355494,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04355429,captopril,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN angiotensin-converting enzyme (ACE)       ACE_HUMAN
NCT04355364,dornase alfa,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04355247,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04355143,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04355052,hydroxychloroquine + camostat mesylate,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04355052,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04354870,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04354805,chlorpromazine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04354805,chlorpromazine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04354805,chlorpromazine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN clathrin-mediated endocytosis (RME)       N.A.
NCT04354714,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04354441,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04354428,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04354428,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04354428,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04354389,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04354389,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04354259,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04353596,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04353336,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04353284,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04353284,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04353284,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04353271,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04352933,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04352933,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04352465,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04352465,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04352465,methotrexate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04352400,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04352400,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04352400,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04351919,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351919,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04351516,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351763,amiodarone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2) TPC2_HUMAN
NCT04351763,verapamil,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN two pore channel subtype 2 (TPC2) TPC2_HUMAN
NCT04351620,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351347,ivermectin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04351295,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04351191,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351191,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351191,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04351191,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04351191,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04351152,lenzilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN
NCT04350684,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04350684,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04350684,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04350671,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04350671,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04350671,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04350450,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04350320,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04350281,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04350281,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04349631,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04349592,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04349592,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04480138,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04349410,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04349410,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04349410,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04349410,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04349410,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04349410,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04349410,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04349410,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04349410,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04349241,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04349228,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04349098,selinexor,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348695,ruxolitinib plus simvastatin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348500,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04348474,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04348474,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04348461,mesenchymal stromal cells,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348435,hb-admscs cell,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04348409,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04347980,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04347915,clevudine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04347889,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04347512,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04347512,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04347239,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5)   CCR5_HUMAN
NCT04347226,bms-986253,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 8 (IL8)       IL8_HUMAN
NCT04347031,mefloquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Preclinical Drug,
NCT04347031,mefloquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Preclinical Drug,
NCT04347031,mefloquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04347031,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04346797,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04346667,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04346667,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04346667,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04346667,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04346667,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04346628,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04346355,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04346329,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04345861,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04345692,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04345653,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04345445,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04345445,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04345419,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04345419,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04345419,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04345419,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04345406,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04345276,danoprevir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04344782,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04344756,heparin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Investigative Agent,
NCT04344600,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04343729,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04344548,allogeneic nk transfer,Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04344457,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04344457,indomethacin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04344444,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04344444,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04344379,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04344379,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04343989,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04343989,clazakizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04343976,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04343768,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04343768,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04343768,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04343768,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04343651,leronlimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C-C chemokine receptor 5 (CCR5)   CCR5_HUMAN
NCT04343001,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04342897,ly3127804,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiopoietin-2 (ANG-2)    ANGP2_HUMAN
NCT04342663,fluvoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04342650,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04342650,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04342650,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04342221,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04342169,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04342156,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341935,linagliptin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN dipeptidyl peptidase 4 (DPP-4)    DPP4_HUMAN
NCT04341870,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04341870,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04341870,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04372186,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04341727,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341727,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04341727,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04341727,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04341727,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341675,sirolimus,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN mammalian target of rapamycin (mTOR)      MTOR_HUMAN
NCT04341493,nitazoxanide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04341493,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341441,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341441,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341207,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04341207,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04341116,tj003234,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,HUMAN colony-stimulating factor (GM-CSF)        CSF2_HUMAN
NCT04341038,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04340557,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04340544,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04340349,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04338958,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04339816,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04339816,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04339712,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04339712,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04339426,atovaquone + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04338906,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04338906,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04338906,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04338906,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04338802,nintedanib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04338698,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04338698,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04338698,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04333472,piclidenoson,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04337359,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04336904,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04336748,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04336410,ino-4800,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04336254,allogeneic human dental pulp stem cells (bsh btc & utooth btc),Cell therapy,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04335552,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04335552,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04335305,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04335136,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04335123,losartan,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN type-1 angiotensin II receptor (AGTR1)    AGTR1_HUMAN
NCT04335071,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04334980,bactrl-spike,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1 Clinical Trial,
NCT04334967,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04334928,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04334512,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04334512,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04334460,bld-2660,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN calpain-2/calpain small subunit 1 dimer (CAPN2/CAPNS1)    CAN2_HUMAN/CPNS1_HUMAN
NCT04334382,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04334382,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04333914,avdoralimab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN C5a receptor (C5aR)       C5AR1_HUMAN
NCT04333914,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04333654,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04333628,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04333628,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04333628,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04333589,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04333550,deferoxamine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04333420,rhace2,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN angiotensin-converting enzyme 2 (ACE2)    ACE2_HUMAN
NCT04333225,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04332991,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04332666,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04332107,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04332094,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04332094,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04332094,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04332042,tofacitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04331899,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04331808,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04331795,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04331795,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04331665,ruxolitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN janus kinase 2 (JAK-2)    JAK2_HUMAN
NCT04331470,levamisole pill + budesonide+formoterol inhaler,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04331470,lopinavir + ritonavir + hydoxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04330690,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04330690,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04330690,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04330690,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04330638,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04330638,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04330638,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04330495,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04330300,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04330300,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04329923,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329923,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329923,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329832,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329832,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04329650,siltuximab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin 6 (IL6)       IL6_HUMAN
NCT04329650,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04329611,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329572,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04329572,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04328961,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328493,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04328493,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04328493,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328480,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04328467,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328285,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328285,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04328272,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04328272,azithromycin,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04327388,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04326790,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04326426,tradipitant,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04325893,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04324606,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04324606,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04324606,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04324606,chadox1 ncov-19,Vaccine,Coronavirus Disease 2019 (COVID-19),Drug in Phase 1/2 Clinical Trial,
NCT04324489,das181,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04324463,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04324463,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04324073,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04324021,emapalumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,HUMAN interferon gamma (IFNG)   IFNG_HUMAN
NCT04324021,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT04323761,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04323761,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04323761,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04323631,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04323592,methylprednisolone,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04323527,chloroquine,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,
NCT04323527,chloroquine,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,
NCT04323527,chloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04322786,angiotensin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT04322682,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04322565,colchicine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04322123,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04322123,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04321616,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04321616,remdesivir,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,SARS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVHSA (RdRp)
NCT04321616,remdesivir,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,MERS-CoV RNA-directed RNA polymerase (RdRp)     R1AB_CVEMC (RdRp)
NCT04321616,remdesivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04321278,hydroxychloroquine + azithromycin,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04321278,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04321174,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04321096,camostat mesylate,Small molecular drug,Severe acute respiratory syndrome (SARS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04321096,camostat mesylate,Small molecular drug,Middle East Respiratory Syndrome (MERS),Investigative Agent,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04321096,camostat mesylate,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN transmembrane protease serine 2 (TMPRSS2) TMPS2_HUMAN
NCT04320615,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04320277,baricitinib,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN cyclin G-associated kinase (GAK)  GAK_HUMAN
NCT04320238,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT04320238,thymosin,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04318444,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04318015,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04317092,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04316377,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04315896,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04315480,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04315298,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04313023,pul-042,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN toll-like receptor 9 (TLR9)       TLR9_HUMAN
NCT04312997,pul-042,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,HUMAN toll-like receptor 9 (TLR9)       TLR9_HUMAN
NCT04312243,nitric oxide,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2 Clinical Trial,
NCT04310228,favipiravir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 RNA-directed RNA polymerase (RdRp)     R1AB_SARS2 (RdRp)
NCT04310228,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT04308668,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT04307693,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT04307693,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT02735707,anakinra,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-1 receptor 1 (IL1R1)  IL1R1_HUMAN
NCT02735707,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT02735707,hydroxychloroquine,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN glycosylation of host receptor (GHR)      N.A.
NCT02735707,lopinavir + ritonavir + hydoxychloroquine,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 2/3 Clinical Trial,
NCT02735707,interferon beta-1a,Protein/peptide drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT02735707,lopinavir + ritonavir,Combination drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,COVID-19 3C-like protease (3CLpro)      R1AB_SARS2 (3CLpro)
NCT02735707,sarilumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
NCT02735707,oseltamivir,Small molecular drug,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,
NCT02735707,tocilizumab,Monoclonal antibody,Coronavirus Disease 2019 (COVID-19),Drug in Phase 3 Clinical Trial,HUMAN interleukin-6 receptor (IL6R)     IL6RA_HUMAN; IL6RB_HUMAN
